Griffiths Richard Ian 4

What Happened

• Richard Ian Griffiths, reported as a 10% owner of Silence Therapeutics plc, sold a total of 1,544,374 shares in a series of open‑market transactions between June 29 and July 6, 2026. The filing does not report per‑share prices or total dollar values for these sales. The transactions are reported as sales (S) rather than purchases — typically a liquidity/portfolio action rather than a bullish insider buy.

Key Details

• Transaction dates and amounts:
  • 2026-06-29: 330,072 shares (sale)
  • 2026-06-30: 169,928 shares (sale)
  • 2026-07-01: 79,180 shares (sale)
  • 2026-07-01: 50,000 shares (sale)
  • 2026-07-02: 50,082 shares (sale)
  • 2026-07-06: 865,112 shares (sale)
• Prices and total dollar values: Not reported in the Form 4 (listed as N/A).
• Shares owned after transaction: Not specified in the filing excerpt provided.
• Footnotes of note:
  • F1: Each American Depositary Share (ADS) is immediately convertible into three ordinary shares at no cost and has no expiration. If the reported securities are ADSs, the ordinary‑share equivalent would be three times the reported amount (i.e., up to ~4.63M ordinary shares).
  • F2: The securities were sold by Cream Capital Limited and Mr. Griffiths personally. Mr. Griffiths is a director and the controlling shareholder of CCL and disclaims beneficial ownership except to the extent of his proportionate pecuniary interest.
• Filing timeliness: The Form 4 was filed July 7, 2026, covering trades from June 29–July 6. Form 4s are generally required within two business days of a transaction; investors may wish to check the full filing for any timeliness flags or explanatory notes.

Context

• Griffiths is a 10% owner and is reported as controlling shareholder of Cream Capital Limited; sales executed through an affiliated entity can reflect institutional liquidity or portfolio management rather than trading by an operating executive. The filing contains no indication these were option exercises or awards — they are reported as open‑market sales. As always, sales by large shareholders reduce their stake but do not by themselves prove a change in company fundamentals.